New BiTE-EV therapy tested for tough leukemia cases
NCT ID NCT06890494
First seen Mar 17, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early-phase study tests whether a new treatment called BiTE-EV is safe and can help adults with relapsed or treatment-resistant acute B-cell leukemia. Only 3 participants will receive the therapy every other day for 1-2 months, followed by regular checkups. The main goals are to see what side effects occur and whether the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.